KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $17.5 million.

  • Rigel Pharmaceuticals' Net Income towards Common Stockholders rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2817.96%. This contributed to the annual value of $17.5 million for FY2024, which is 169.61% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at $17.5 million for FY2024, which was up 169.61% from -$25.1 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $17.5 million in FY2024 and a low of -$58.6 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$22.1 million, with a median of -$25.1 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 226.97% in 2022, then soared by 169.61% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Net Income towards Common Stockholders stood at -$29.7 million in 2020, then skyrocketed by 39.77% to -$17.9 million in 2021, then plummeted by 226.97% to -$58.6 million in 2022, then spiked by 57.16% to -$25.1 million in 2023, then spiked by 169.61% to $17.5 million in 2024.